Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | not in the Protein Atlas | 0.00 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 11762
Sealed predictions
- CLECL1 in dopamine neurons, braak+0.42 (p 0.258) → +0.21 (p 0.586)receipt 11769
Swarm cases
receipt 11769: CLECL1 in dopamine neurons, braak
- power
- full sample +0.36 (p 0.137, n 18), 95% CI -0.12 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.27 (p 0.277, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.31 (p 0.214, n 18). could be the mix.
- skeptic
- leave-one-out range +0.30 to +0.54, sign flips 0; without severely affected donors +0.36 (p 0.137, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CLECL1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts